Bhavin Jitendra Dumaswala

Bhavin Dumaswala practices at St Lukes University Hospital Bethlehem in Bethlehem, Pennsylvania.

Bhavin Dumaswala's NPI, 1437581006, was assigned on August 6, 2013. Bhavin Dumaswala holds Pennsylvania license MD468263.

Bhavin Dumaswala's primary practice is St Lukes University Hospital Bethlehem, at 801 Ostrum St, Bethlehem, PA 18015 in Northampton County. The practice phone is (610) 954-4000.

Bhavin Dumaswala's primary practice is St Lukes University Hospital Bethlehem in Bethlehem, Pennsylvania. Bhavin Dumaswala is also affiliated with St. Luke's University Hospital - Bethlehem Campus. The medical group on file is St. Luke's South Mountain Family Practice. Dmand AI also links Bhavin Dumaswala to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Bhavin Dumaswala practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Bhavin Dumaswala's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Bhavin Dumaswala is licensed in Pennsylvania.

CMS data shows 2,954 Medicare services from Bhavin Dumaswala across 21 procedure codes in 2024, for 1,617 Medicare patients. Medicare paid $117,431 for them.

CMS counts 1,617 Medicare patients who saw Bhavin Dumaswala in 2024. The largest group is 65 to 74, with 605 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Bhavin Dumaswala's median patient age at 72, with 47% women.

In 2024, Bhavin Dumaswala wrote 3,110 Medicare Part D claims for 444 patients. 82% of them were for generic drugs. CMS names the drug for 2,874 of them, across 37 drugs with 11 or more claims each, at $446,372 in total drug cost. In 2023, CMS named 2,307 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Bhavin Dumaswala for performance year 2024, reported through an alternative payment model (APM). Bhavin Dumaswala accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Bhavin Dumaswala as offering telehealth.

CMS Open Payments shows 9 general payments to Bhavin Dumaswala from 6 drug and device companies from 2016 to 2019. Food and beverage make up the largest share, 76% of the total. Novartis Pharmaceuticals Corporation paid the most, $154.